The U.S. CAR-T cell therapy market is on a powerful upward trajectory, driven by the rising burden of cancer across the country and a wave of regulatory approvals for next-generation immunotherapies. According to Fortune Business Insights, the market was valued at USD 3.00 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 18.7% through 2032, making it one of the fastest-growing segments within oncology therapeutics.
Chimeric antigen receptor (CAR) T-cell therapy is a groundbreaking form of immunotherapy that engineers a patient's own T cells in laboratory settings to recognize and destroy cancer cells. This personalized approach has demonstrated strong efficacy in treating blood cancers, including leukemia, non-Hodgkin lymphoma, and multiple myeloma. With over 1.2 million Americans diagnosed with cancer each year, per the National Cancer Institute, demand for advanced treatment solutions like CAR-T continues to grow.
The primary driver behind market growth is the increasing prevalence of blood cancers and the rising number of FDA approvals for cell-based therapies. In March 2022, the FDA approved Carvykti (ciltacabtagene autoleucel), developed by Janssen, as a treatment for adults with relapsed or refractory multiple myeloma. Additionally, in June 2022, Breyanzi, a CAR-T therapy by Bristol Myers Squibb, received approval for large B-cell lymphoma patients ineligible for transplant.
Research and development activity is another strong catalyst. According to a 2022 report by Cell & Gene, approximately 750 active CAR-T therapies were in development globally, with 375 in clinical phases. Innovations such as the FasT CAR-T technology — capable of reducing T-cell manufacturing time to just 24 hours — are also expected to expand access and scalability.
Despite promising growth, the high cost of therapy remains a significant barrier. For example, a one-time infusion of cilta-cel (Carvykti) carries a list price of USD 465,000, limiting widespread adoption among patients. Manufacturing complexity and limited T-cell availability further constrain market expansion.
By drug type, Yescarta holds the largest market share, supported by its demonstrated survival benefits — including a 27.4% reduction in mortality risk and a 38% improvement in overall survival in the Phase-3 ZUMA-7 trial reported by Gilead Sciences in June 2023. By indication, the multiple myeloma segment is expected to register the highest CAGR during the forecast period, given its rising incidence — with the American Cancer Society estimating a lifetime risk of 1 in 132 people.
By end user, hospitals dominate the market, backed by a large inpatient and outpatient base. The American Hospital Association reported approximately 6,093 hospitals operating across the U.S. in 2022, providing a broad infrastructure for advanced treatment delivery.
Prominent companies shaping the U.S. CAR-T cell therapy landscape include:
These players are actively pursuing collaborations, acquisitions, and new product approvals to strengthen their market positions. Notably, in May 2023, Janssen Biotech partnered with Cellular Biomedicine Group (CBMG) to develop next-generation CAR-T therapies for B-cell malignancies.
The U.S. CAR-T cell therapy market is poised for robust long-term expansion, anchored by scientific innovation, increasing patient awareness, and a supportive regulatory environment. As manufacturing efficiencies improve and new indications receive approval, CAR-T therapy is expected to become a cornerstone of precision oncology in the United States.
Source: Fortune Business Insights – U.S. CAR-T Cell Therapy Market
Q1. What is the U.S. CAR-T cell therapy market size and share? According to Fortune Business Insights, the U.S. CAR-T cell therapy market was valued at USD 3.00 billion in 2023. It is projected to grow at a CAGR of 18.7% from 2024 to 2032. Yescarta held the largest share by drug type in 2022, while hospitals dominated the end-user segment. Key players such as Novartis AG, Bristol-Myers Squibb, Gilead Sciences, and Johnson & Johnson collectively account for a significant portion of the overall market share.
Q2. What are the major growth drivers for the U.S. CAR-T cell therapy market? The primary drivers include the rising prevalence of blood cancers such as leukemia, multiple myeloma, and non-Hodgkin lymphoma, coupled with increasing FDA approvals for cell-based therapies. Growing R&D investment, expanding clinical pipelines with over 750 active CAR-T therapies globally, and technological advancements like FasT CAR-T manufacturing are further accelerating market growth.
Q3. What challenges does the U.S. CAR-T cell therapy market face? The most notable challenge is the high treatment cost — a single infusion can exceed USD 465,000 — limiting patient access and reimbursement coverage. Other barriers include the complexity and time required for T-cell manufacturing, along with limited availability of qualified treatment centers capable of administering these advanced therapies.